United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized progress in the company’s clinical programs, particularly the ADVANCE OUTCOMES study for ralinepag and the TETON-1 trial for Tyvaso in pulmonary fibrosis. President Michael Benkowitz noted that although revenue was flat sequentially, o

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Moby summary of BETA Technologies, Inc.'s Q2 2026 earnings call

BETA Technologies Inc (BETA) reports record Q2 revenue and nearly hits $4B backlog target, while navigating certification progress and significant cash burn.

CEO Rothblatt calls H1 2026 "one of the most consequential periods" in company history.

Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.

Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.

In the past week, United Therapeutics reported second-quarter 2026 results showing sales of US$783.3 million, a slight year-on-year decline, while net income rose to US$333 million and diluted EPS increased to US$7.27, alongside continued share repurchases under its US$1.50 billion buyback program. At the same time, publication of positive phase 3 ADVANCE OUTCOMES data for investigational PAH therapy ralinepag and its recent FDA filing added a new layer of potential to United Therapeutics’...

MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with

United Therapeutics' (UTHR) Q2 miss for Tyvaso reflected pressure from rising competition, though th

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Moby summary of United Therapeutics Corporation's Q2 2026 earnings call

Company advances key regulatory submissions for Tyvaso and ralinepag while navigating competitive pressures in the inhaled prostacyclin market.

United Therapeutics (NASDAQ:UTHR) reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized TYVASO therapy. Company executives said they expect stronger performance in the second half of the ye

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

United Therapeutics (UTHR) delivered earnings and revenue surprises of +6.60% and -2.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 million. Its GAAP profit of $7.27 per share was 5.9% above analysts’ consensus estimates.

UTHR vs. SDZNY: Which Stock Is the Better Value Option?

(Bloomberg) -- Executives and investors tied to the AI supply chain were among the biggest insider sellers in the second quarter, taking advantage of a sharp — and volatile — rally in technology stocks.Most Read from BloombergUS Intercepts Iran Attack on Bases, Puncturing Days of CalmSK Hynix Profit Disappoints, Spending Soars to $31 BillionNvidia’s $750 Billion in Deals Reignite Circular AI FearsChip Rout Deepens on Circular Funding, China Competition FearsApple Set to Make Big Smart Home Push

Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while maintaining $353.1 million in equity value.

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liquidia is expanding the use of its pulmonary hypertension drug YUTREPIA into additional indications after early commercial traction. Ongoing patent litigation with United Therapeutics has moved in a direction that appears favorable for Liquidia, with a delayed ruling reducing the risk that YUTREPIA is removed from the market. These developments could affect the opportunity for NasdaqCM:LQDA shareholders by influencing the size and durability of YUTREPIA's addressable market. Liquidia...